ABSTRACT Introduction: The extent to which intratumoral heterogeneity of programmed death ligand 1 (PD-L1) expression causes discordance of PD-L1 expression between paired samples remains unclear. Here, PD-L1 status was compared between whole sections from NSCLCs and the corresponding tissue microarrays (TMAs) serving as surrogate biopsy specimens.
Methods: PD-L1 expression was evaluated by 22C3 immunohistochemistry assay on 190 archival surgical specimens and matched to the TMA results. PD-L1 expression was determined by the tumor proportion score (TPS) and classified as TPS lower than 1%, TPS of 1% to 49%, and TPS of 50% or higher. Agreement statistics were used.
Results: The percentage of PD-L1 expression on tumor cells differed greatly between individual TMAs and matched surgical specimens. When PD-L1 TPS was adopted, a total of 36 of 190 discordance cases (18.9%) were observed, with a k-value of 0.630 between paired samples. The TMAs underestimated or overestimated PD-L1 status in 19 of 36 (52.8%) and 17 of 36 (47.2%) of the matched surgical specimens, respectively (p ¼ 0.118). The discordance rate was much lower in cases with a PD-L1 TPS lower than 1% compared with in cases with a TPS of 1% to 49% and TPS of 50% or higher (18.4% versus 56.7% and 43.3%, p < 0.001). When a TPS of 50% or higher was used as the cutoff, the discordance rate of PD-L1 TPS less than 50% was further reduced to 7.5%. Such discrepancies were due mainly to intratumoral heterogeneity of PD-L1 expression and nonsignificant association with clinicopathological features.
Conclusions: PD-L1 expression in TMAs correlates moderately well with that in the corresponding surgical specimens, indicating that evaluating PD-L1 expression in diagnostic biopsy specimens could be misleading in defining sensitivity to pembrolizumab treatment yet may be reliable as a way to exclude patients with a PD-L1 TPS less than 50% from first-line pembrolizumab treatment.
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Introduction
Blockade of immune checkpoints has recently emerged as a novel treatment for various cancers. In particular, monoclonal antibodies targeting programmed cell death 1 (PD-1) or its ligand (PD-L1) have been extensively studied in lung cancer treatment, and their roles as first-line 1 or second-line 2-8 treatment in the management of patients with advanced NSCLC are well established.
Pembrolizumab is a humanized anti-PD-1 monoclonal antibody of the immunoglobulin G4 k isotype that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Reports from three high-profile clinical trials have shown clinical efficacy in both chemonaive and previously treated patients with advanced NSCLC. 1, 2, 9 In a phase 1 study, pembrolizumab has demonstrated promising response rates in patients with NSCLC that correlated with PD-L1 expression on tumor cells. 9 Subsequently, results from the phase 2/3 KEYNOTE-010 study showed that pembrolizumab prolonged overall survival compared with docetaxel in previously treated patients with advanced NSCLC who had PD-L1 immunohistochemical (IHC) positive expression (at least 1% of tumor cells). 2 Recently, a phase 3 KEYNOTE-024 trial enrolled 305 patients with previously untreated advanced NSCLC who had PD-L1 expression on at least 50% of tumor cells; they received either pembrolizumab or first-line platinumbased chemotherapy. 1 In this study, pembrolizumab was associated with significantly longer progression-free survival and overall survival and with a higher response rate than platinum-based chemotherapy; the median progression-free survival was 10.3 months in the pembrolizumab group (95% confidence interval [CI]: 6.7-not reached) versus 6.0 months in the chemotherapy group (95% CI: 4.2-6.2), the estimated rate of overall survival at 6 months was 80.2% versus 72.4% (95% CI: 0.41-0.89, p ¼ 0.005), and the respective response rates were 44.8% and 27.8%. 1 On the basis of these studies, the U.S. Food and Drug Administration-approved 22C3 assay was used as a companion diagnostic to predict the clinical response to pembrolizumab treatment.
Currently, clinical application of the 22C3 PD-L1 biomarker is essentially confined to patients with advanced NSCLC and the 22C3 PD-L1 cutoff point is set on the basis of biopsy specimens. 1, 2, 9 Small tissue specimens such as bronchial or transthoracic biopsies will be the only available material from cancer tissue for diagnostic use in some clinical circumstances, especially in patients with advanced-stage NSCLC. Several studies have noted significant intertumoral heterogeneity of PD-L1 expression across different types of cancers. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] However, the frequency of discrepancies of 22C3 PD-L1 intratumoral expression on small tissue specimens in NSCLC, which may affect clinical decision making, remains largely unclear. Tissue microarray (TMA) cores are useful surrogates for small tissue specimens. This technology has been developed over recent years and is mainly used to identify biomarkers useful for the correct identification and characterization of tumors. Moreover, TMA technology has been applied to define predictive biomarkers of response to a given therapy and/or to find potential new targets for biological therapy in retrospective studies. 24, 25 To better understand to the extent to which the intratumoral heterogeneity of PD-L1 expression leads to discrepancies in PD-L1 expression in paired samples, we compared the PD-L1 staining results obtained on surgical specimens with those obtained on corresponding TMAs from NSCLCs by using the 22C3 PD-L1 IHC assay.
Patients and Methods

Patients and Tissue Samples
Archival formalin-fixed, paraffin-embedded tissue sections were selected from a series of 190 patients who had undergone surgical resection for NSCLC at the Fujian Medical University Cancer Hospital between January 2008 and December 2010. None of the patients were treated before surgery. The clinicopathological information of patients was collected from the clinical records and pathology reports. The pathological TNM stage was reassigned according to the eighth edition of TNM staging, 26 and lung tumor histological subtypes were reclassified according to the 2015 WHO classification for lung tumors. 27 The study design was approved by the Ethical Committee of Fujian Cancer Hospital, and written informed consent was obtained from all patients.
Construction of Paired TMAs
The tissue slides were stained with hematoxylin and eosin and used as a guide to select representative tumor regions of the tumor from which to obtain the individual core needle biopsy samples. After 10 serial pathological section samples were obtained, one 2-mm-diameter core was punched from selected representative tumor areas of each donor tissue block and introduced into a previously prepared 35 Â 25-mm recipient paraffin block with 2.0-mm spacing after hosting holes had been made in the blocks with a tissue microarrayer. After the TMAs were constructed, 4-mm sections were cut from the TMA blocks to generate TMA slides for 22C3 IHC analyses.
PD-L1 Immunohistochemistry
PD-L1 expression was detected by the murine 22C3 anti-human PD-L1 antibody in the Autostainer Link 48 platform (Merck and Co., Inc., Hong Kong). Each staining run contained positive and negative controls along with a negative isotype-matched antibody control for each sample. Two board-certified pathologists (C. L. and D. H.) independently evaluated all stained slides for PD-L1 membrane staining. All areas in a tissue section were observed to appropriately evaluate the expression of PD-L1 on tumor cells. Following the standard recommendation of prior publications, PD-L1 protein expression was determined by using the tumor proportion score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining. PD-L1 expression was classified into three levels: TPS lower than 1%, TPS of 1% to 49%, and TPS of 50% or higher. 1, 2, 9 The agreement analysis showed that the k value varied from 0.94 to 1.0 among the two pathologists for the assessment of PD-L1 TPS. The discordant cases were reviewed to reach a final consensus classification.
Statistical Analysis
Descriptive statistics were used to summarize patient demographics and results. Agreement statistics (Cohen's k coefficient) were used to assess heterogeneity of PD-L1 expression between paired lesions. The level of concordance was classified according to k value as poor (<0.4), fair (0.40-0.75), or substantial (!0.75). Discordance was defined when the evaluation of PD-L1 expression was different between the excision specimens and paired TMAs according to three-level or two-level PD-L1 TPS classification (using TPS !50% or TPS !1% as the cutoff). The CIs were calculated by the modified Wald method. The c 2 test or Fisher's exact test was used to compare proportions within groups. Statistical analyses were performed by using SPSS 16.0 software (SPSS, Inc., Chicago, IL). All tests were two sided. Statistical significance was set at p less than 0.05.
Results
Patient Characteristics and Pathological Findings
A total of 190 patients were eligible for the study, and their characteristics are summarized in Table 1 . The median age at diagnosis was 56 years (range 34-78 years), and the Eastern Cooperative Oncology Group performance status was 0 for all patients.
Comparison of PD-L1 Test Results in Excision Specimens and Paired TMAs
PD-L1 was usually expressed at the membrane of cancer cells; heterogeneous distribution of PD-L1 staining was observed within a single section of tumor tissue. A PD-L1 TPS of 1% to 49% and a TPS of 50% or higher were observed in 25.8% and 11.1% in excision specimens and in 19.5% and 13.7% of paired TMAs, respectively. Although the distribution was similar in the two groups, the percentage of 22C3 PD-L1 expression on tumor cells in individual TMAs correlated poorly with that in the corresponding resected tumor, as shown in Figure 1 .
A total of 36 discordance cases were reviewed in terms of adopting the three-level classification of PD-L1 TPS; the overall discordance rate was 18.9% (95% CI: 13.4%-24.5%), and the k value was 0.630 (moderate agreement). The TMAs underestimated or overestimated PD-L1 expression on tumor cells compared with in the corresponding excision samples in 19 of 36 cases (52.8%) and 17 of 36 cases (47.2%), respectively (p ¼ 0.118) ( Table 2) . In this population, the discordance rate was much lower in cases with a PD-L1 TPS lower than 1% compared with in those with a PD-L1 TPS of 1% to 49% and a TPS of 50% or higher: the rates were 18.4% (95% CI: 11.9%-24.9%) versus 56.7% (95% CI: 44.1%-69.2%) and 43.3% (95% CI: 25.6%-61.1%), respectively (p < 0.001) (see Table 2 ). When a TPS of 1% or higher and a TPS of 50% or higher were used as the cutoff, the k values increased to 0.711 and 0.685, respectively. Accordingly, the overall discordance rates were decreased to 13.2% (95% CI: 8.4%-18.0%) and 6.8% (95% CI: 3.3%-10.4%), respectively (p ¼ 0.002) (see Table 2 ). We compared PD-L1 expression of the TMAs with the corresponding area of the excision specimens and found that there was high concordance of PD-L1 expression between them (representative images of 22C3 PD-L1 IHC staining in excision specimens and paired TMAs are shown in Fig. 2A-C) . Only five of 190 cases (2.6%) showed PD-L1 expression on TMAs completely opposite that of the corresponding area of the excision specimens; two were positive on the excision specimens but entirely negative on the TMAs, and three were positive on the TMAs but entirely negative on the excision specimens (representative images are shown in Fig. 2D ). We repeated the 22C3 PD-L1 assay and confirmed the PD-L1 expression status in these cases, which are indicated by an asterisk in Figure 1 .
We also evaluated the correlation of discordance of PD-L1 expression with clinicopathological features and found no significant association with age, sex, smoking status, histological subtype, or tumor stage (p > 0.05) (see Supplementary Table 1 ).
Discussion
The aim of our study was to explore the extent to which the intratumoral heterogeneity of 22C3 PD-L1 expression may lead to discrepancies in PD-L1 expression in surgical samples and their matched TMAs that are used as surrogates for core biopsy specimens in NSCLC. The results showed that the percentage of 22C3 PD-L1 expression on tumor cells assessed in individual TMAs correlated poorly with that in the corresponding resected tumor in a cohort of 190 patients with NSCLC. With the adoption of the three-level PD-L1 TPS classification, a total of 36 of 190 discordant cases (18.9%) were found in this study. In addition, our study clarified that most discordances between excision specimens and paired TMAs were attributed to intratumoral heterogeneity of PD-L1 expression.
Currently, clinical application of the 22C3 PD-L1 biomarker is essentially confined to patients with advanced NSCLC. We should keep in mind that the 22C3 PD-L1 expression cutoff was set on the basis of biopsy specimens. 1,2,9 Therefore, we did not use the PD-L1 status in surgical specimens as a predefined definitive standard in this study, as this will be determined in the context of the response to pembrolizumab. However, this degree of discrepant expression potentially challenges the current practice of determining which patients should receive pembrolizumab.
Recently, several studies concerning intratumoral and intertumoral heterogeneity of PD-L1 expression across different types of cancers have been published. [10] [11] [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] Among these studies, there are few that assessed the intratumoral heterogeneity of PD-L1 expression by using different PD-L1 assays in lung cancer. Kitazono et al. 23 compared 79 diagnostic biopsy specimens with corresponding subsequent surgical specimens in terms of PD-L1 expression assessed by polyclonal antibody 4059 from ProSci (Poway, CA). The results showed a good concordance between the biopsy samples and resected specimens (concordance rate 92%). In contrast, the study carried out by Ilie et al. 22 indicated that PD-L1 expression, as detected by the SP142 clone assay, was frequently discordant between the 160 surgically resected samples and matched biopsy specimens: the overall discordance rate was 48% and the k value was only 0.218 (poor agreement). Similarly, our study showed poor agreement of PD-L1 expression between individual surgical specimens and paired TMAs. However, with adoption of the three-level PD-L1 TPS classification, the PD-L1 status between surgical specimens and paired TMAs improved to moderate agreement (the overall discordance rate was 18.9% and the k value was 0.630). Furthermore, our results showed that the discordances between excision specimens and paired TMAs were randomly scattered, which was obviously different from the results in the study conducted by Ilie et al., 22 in which biopsy specimens overwhelmingly underestimated the PD-L1 status observed on the whole tissue sample. First, there was no significant difference between underestimated samples and overestimated samples in TMAs. Second, we also found that discordance of PD-L1 expression was not significantly association with age, sex, smoking status, histological subtype, or tumor stage.
One of the reasons for these conflicting results could be the different PD-L1 assays used in the various studies. Recently, some studies have found that the SP142 assay exhibited fewer stained tumor cells overall compared with other assays (SP263, 22C3, and 28-8). [28] [29] [30] More importantly, among these PD-L1 antibodies, only the 22C3 pharmDx assay (Agilent Technologies, Santa Clara, CA), which is linked to the use of pembrolizumab, has obtained regulatory status as a companion diagnostic. In the study, we found that the discordance rate was lower (18.4%) in cases with a PD-L1 TPS lower than 1% compared with in those with a PD-L1 TPS of 1% or higher. It seemed to correspond to the low rate of response to pembrolizumab of 8.1% (95% CI: 3.3-15.9) in patients with NSCLC with a PD-L1 TPS lower than 1%. 9 The discordance rate of a PD-L1 TPS of 0% to 49% was only 7.5% when a PD-L1 TPS of 50% or higher was used as the cutoff (see Table 2 ), which indicates that it could be reliable to exclude patients from first-line pembrolizumab treatment when PD-L1 staining is found on 0% to 49% of tumor cells, no matter what kind of sample is taken.
Our study was potentially limited by a few factors. First, a single paired lesion was obtained from each surgical specimen. Multifocal lung cancer specimens as a model could provide more information to assess intratumoral heterogeneity. Second, all samples were from patients who had not had previous PD-1 or PD-L1 therapy. We could evaluate only the comparison of PD-L1 expression between paired tissues and not the clinically meaningful comparisons.
Despite the aforesaid limitations, we determined that there was a significant difference in PD-L1 expression between excision specimens and paired TMAs, which indicates that PD-L1 testing on small tissue specimens may lead to misclassification of the PD-L1 expression status. It could be necessary to obtain multiple biopsy samples to enhance the predictive value of 22C3 PD-L1 expression.
